Ocuphire Pharmas investors will be pleased with their 21 percent return over the last year - Yahoo New Zealand News

OCUPDelisted Stock  USD 1.13  0.06  5.04%   
Slightly above 61% of Ocuphire Pharma's investor base is looking to short. The analysis of current outlook of investing in Ocuphire Pharma suggests that many traders are alarmed regarding Ocuphire Pharma's prospects. Ocuphire Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Ocuphire Pharma. Many technical investors use Ocuphire Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
Ocuphire Pharmas investors will be pleased with their 21 percent return over the last year Yahoo New Zealand News

Read at news.google.com
Google News at Macroaxis
  

Ocuphire Pharma Fundamental Analysis

We analyze Ocuphire Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocuphire Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocuphire Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Debt To Equity

Debt To Equity Comparative Analysis

Ocuphire Pharma is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Ocuphire Pharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ocuphire Pharma stock to make a market-neutral strategy. Peer analysis of Ocuphire Pharma could also be used in its relative valuation, which is a method of valuing Ocuphire Pharma by comparing valuation metrics with similar companies.

Peers

Ocuphire Pharma Related Equities

EYENEyenovia   23.73   
0%
100.0%
RNAZTranscode Therapeutics   11.76   
0%
49.0%
FBIOFortress Biotech   9.52   
0%
40.0%
SLSSellas Life   2.56   
0%
10.0%
RIGLRigel Pharmaceuticals   2.34   
0%
9.0%
KODKodiak Sciences   2.02   
0%
8.0%
CKPTCheckpoint Therapeutics   1.74   
0%
7.0%
FBIOPFortress Biotech   0.77   
0%
3.0%
PLXProtalix Biotherapeutics   1.75   
7.0%
0%
CGTXCognition Therapeutics   2.44   
10.0%
0%
EYPTEyepoint Pharmaceuticals   2.49   
10.0%
0%
RVPHReviva Pharmaceuticals   2.61   
10.0%
0%
MBIOMustang Bio   4.76   
20.0%
0%
RVPHWReviva Pharmaceuticals   9.52   
40.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Other Consideration for investing in Ocuphire Stock

If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios